Premium
Introduction to special issue: Overview of Alzheimer's Disease Neuroimaging Initiative
Author(s) -
Weiner Michael W.,
Veitch Dallas P.
Publication year - 2015
Publication title -
alzheimer's and dementia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 6.713
H-Index - 118
eISSN - 1552-5279
pISSN - 1552-5260
DOI - 10.1016/j.jalz.2015.05.007
Subject(s) - alzheimer's disease neuroimaging initiative , neuroimaging , disease , positron emission tomography , cognitive impairment , medicine , magnetic resonance imaging , psychology , neuroscience , radiology
The Alzheimer's Disease Neuroimaging Initiative (ADNI), designed as a naturalistic longitudinal study to develop and validate magnetic resonance, positron emission tomography, cerebrospinal fluid, and genetic biomarkers for use in AD clinical trials, has made many impacts in the decade since its inception. The initial 5‐year study, ADNI‐1, enrolled cognitively normal, mild cognitive impairment (MCI) and AD subjects, and the subsequent studies (ADNI‐GO and ADNI‐2) added early‐ and late‐MCI cohorts. The development of standardized methods allowed comparison of data gathered across multiple sites, and these data are available to qualified researchers without embargo. ADNI data have been used in >600 publications including those describing relationships between biomarkers, improved methods for disease diagnosis and the prediction of future decline, and identifying novel genetic AD risk loci. ADNI has provided a framework for similar initiatives worldwide.